Clinical and procedural factors related to stent thrombosis

Authors

  • Guillermo Pacheco González Hospital Militar Central “Dr. Luis Díaz Soto”
  • Ángel G. Obregón Santos Centro de Investigaciones Médico Quirúrgicas
  • Ronald Aroche Aportela Centro de Investigaciones Médico Quirúrgicas
  • Héctor Conde Cerdeira Centro de Investigaciones Médico Quirúrgicas
  • Myder Hernández Navas Hospital General Docente “Enrique Cabrera”
  • Julio C. Gandarilla Sarmientos Instituto de Cardiología y Cirugía Cardiovascular

Keywords:

coronary artery disease, angioplasty, blood vessel prosthesis, thrombosis, risk factors

Abstract

Introduction and Objectives: Stent thrombosis is a complication after percutaneous coronary intervention associated with high mortality and morbidity. Despite the use of dual antiplatelet therapy (aspirin and clopidogrel) and optimization of the technique, its incidence has not disappeared. The objective of this research was to determine the risk factors for thrombosis of the bare metal stents. Method: A retrospective descriptive study was performed. Out of the 2,014 revascularized arteries at the Medical-Surgical Research Center in Havana, Cuba, between August 1997 and February 2009, the 289 redo ones were selected. Results: thrombosis of the conventional metal stents was present in 20 arteries, of which 11 corresponded to the anterior descending artery, and the highest incidence occurred in the first 24 hours and after 30 days. Diabetes mellitus was a risk factor for thrombosis (OR = 3.06) and the release pressure of less than 10 atmospheres (OR = 3.70) and complex lesions of types B2 and C (OR = 8.80), all with statistical significance (p <0.05). Conclusions: The highest incidence of bare metal stent thrombosis was on the first day of revascularization after the termination of dual antiplatelet therapy and located in the anterior descending artery. Diabetes mellitus, complex lesions and low pressures of stent release, behaved as risk factors for thrombosis with statistically significant results.

Downloads

Download data is not yet available.

References

1. Balaguer-Malfagón JR, Pomar-Domingo F, Vilar-Herrero JV, Planas-del Viejo AM, Pérez-Fernández E. Trombosis del stent en la era moderna: incidencia, consecuencias y factores predictores. Rev Esp Cardiol. 2006;59(8):842-5.

2. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ. Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials. Circulation. 2001;103;1967-71.

3. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT, et al. “Off-label” stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51(6):607-14.

4. Íñiguez Romo A. Trombosis de los stents farmacoactivos. Rev Esp Cardiol. 2008;61(7):674-7.

5. US Food and Drug Administration [sitio web en Internet]. Silver Spring; 2006 [actualizado 21 Dic 2008]. Disponible en: http://www.fda.gov/ohrms/dockets/ac/cdrh06.html#circulatory

6. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584-91.

7. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1440-55.

8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-51.

9. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-9.

10. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369 (9562):619-21.

11. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.

12. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371(9630):2134-43.

13. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents evolving concepts and perspectives. J Am Coll Cardiol. 2007;50 (2):119-27.

14. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-9.

15. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159-68.

16. Jiménez- Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, Gómez-Hospital JA, et al. Eficacia de la implantación del stent recubierto de rapamicina en pacientes diabéticos con vasos muy pequeños (menor e igual a 2,25 mm). Subanálisis del estudio DIABETES. Rev Esp Cardiol. 2006;59(10):1000-7.

17. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-48.

18. Doyle B, Rihal CS, O’Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007(21);116:2391-8.

19. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al; TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353-63.

20. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon postdilation. J Am Coll Cardiol. 2005;46(4):613-20.

Downloads

Published

2012-06-01

How to Cite

1.
Pacheco González G, Obregón Santos Ángel G, Aroche Aportela R, Conde Cerdeira H, Hernández Navas M, Gandarilla Sarmientos JC. Clinical and procedural factors related to stent thrombosis. CorSalud [Internet]. 2012 Jun. 1 [cited 2025 Oct. 2];4(2):97-102. Available from: https://revcorsalud.sld.cu/index.php/cors/article/view/1211

Issue

Vol. 4 No. 2 (2012)

Section

ORIGINAL ARTICLES

Categories

License

Copyright (c) 2012 CorSalud

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.